The bioeconomy continues to emerge as a significant component of the U.S. economy. Domestic revenues from genetically modified systems are growing at approximately 15% annually, much faster than the economy as a whole. The total 2012 U.S. revenues from genetically modified systems, hereafter the Genetically Modified Domestic Product (GMDP), reached at least $350 billion, the equivalent of approximately 2.5% of GDP, up from $300 billion in 2010.
For comparison, according to IHS iSuppli, the 2012 global revenues for the semiconductor industry amounted to $322 billion. Remarkably, assuming a 2011-12 GDP annual growth rate of 2.5%, the two year, $50 billion increase in GMDP accounted for almost 7% of total U.S. GDP growth.
In 2012, global revenues from biologics reached $125 billion. In 2012, global planting of GM crops increased by 6%, reaching a total of 170 million hectares. U.S. revenues from industrial biotech (fuels, enzymes, and materials) reached at least $125 billion in 2012.
Read full, original article: The U.S. Bioeconomy in 2012 reached $350 billion in revenues, or about 2.5% of GDP
